Department of Pharmacology, Zhongshan School of Medicine, and Vascular Research Center, Sun Yat-Sen University, Guangzhou 510089, People's Republic of China.
Eur J Pharmacol. 2011 Feb 10;652(1-3):104-10. doi: 10.1016/j.ejphar.2010.11.017. Epub 2010 Nov 29.
Recently, it was revealed that the dysfunction of transmembrane Ca(2+) transport, results in an increase in intracellular Ca(2+)Ca(2+), which is involved in the process of atherosclerosis. We previously demonstrated that ginsenoside-Rd, a purified component from panax notoginseng, is a voltage-independent Ca(2+) channels blocker. In this study, we investigated the effects of ginsenoside-Rd on atherosclerosis and the underlying mechanisms in apolipoprotein E deficient (apoE(-/-)) mice and RAW264.7 cells. Atherosclerotic plaques were stained by Red oil O staining. Ca(2+) influx was measured by Fura-2 dyed Mn(2+) quenching. Intracellular cholesterol and uptake of lipid was assayed by enzymatic, fluorometric method and DiI-labeled Ox-LDL. Western blot was used to determine protein expression. We found that Ginsenoside-Rd (20mg/kg/day. i.p.) significantly reduced the atherosclerotic plaque areas, oxidized low-density lipoprotein (ox-LDL) uptake and thapsigargin and l-oleoyl-2-acetyl-glycerol (OAG, membrane-permeable diacylglycerol analog)-induced Ca(2+) influx in macrophages from high-fat diet apoE(-/-) mice. In vitro, 20μM ginsenoside-Rd significantly inhibited ox-LDL-induced foam cell formation and the increase of thapsigargin- and OAG-induced Ca(2+) influx. Ox-LDL induced an increase in scavenger receptor A (SR-A) expression, and ginsenoside-Rd inhibited this effect of ox-LDL significantly. The results suggest that ginsenoside-Rd prevents the development of atherosclerosis. The underlying mechanism may be related to the inhibition of Ca(2+) influx through voltage-independent Ca(2+) channels, resulting in the inhibition of SR-A activity and expression, followed by reductions of ox-LDL uptake and cholesterol accumulation in macrophages.
最近的研究揭示,跨膜 Ca(2+)转运的功能障碍会导致细胞内 Ca(2+)浓度升高Ca(2+),这与动脉粥样硬化的发生过程有关。我们之前的研究表明,人参皂苷-Rd 是从三七中提取的一种成分,是一种电压非依赖性 Ca(2+)通道阻断剂。在这项研究中,我们研究了人参皂苷-Rd 对载脂蛋白 E 缺陷(apoE(-/-))小鼠和 RAW264.7 细胞中动脉粥样硬化的影响及其潜在机制。采用红油 O 染色法对动脉粥样硬化斑块进行染色。通过 Fura-2 染色 Mn(2+)淬灭法测量 Ca(2+)内流。通过酶法、荧光法和 DiI 标记的 Ox-LDL 测定细胞内胆固醇和脂质摄取。采用 Western blot 法测定蛋白表达。我们发现,人参皂苷-Rd(腹腔注射,20mg/kg/天)显著减少高脂饮食 apoE(-/-)小鼠巨噬细胞中的动脉粥样硬化斑块面积、氧化型低密度脂蛋白(ox-LDL)摄取以及 thapsigargin 和 l-油酰-2-乙酰甘油(OAG,膜通透性二酰基甘油类似物)诱导的 Ca(2+)内流。在体外,20μM 人参皂苷-Rd 显著抑制 ox-LDL 诱导的泡沫细胞形成和 thapsigargin 和 OAG 诱导的 Ca(2+)内流增加。ox-LDL 诱导清道夫受体 A(SR-A)表达增加,而人参皂苷-Rd 显著抑制 ox-LDL 的这种作用。结果表明,人参皂苷-Rd 可预防动脉粥样硬化的发生。其潜在机制可能与抑制电压非依赖性 Ca(2+)通道的 Ca(2+)内流有关,从而抑制 SR-A 活性和表达,随后减少巨噬细胞中 ox-LDL 的摄取和胆固醇的积累。